{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:49:51Z","timestamp":1762004991163},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s13730-018-0308-3","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T13:02:15Z","timestamp":1517576535000},"page":"121-126","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition"],"prefix":"10.1007","volume":"7","author":[{"given":"Yamila","family":"Goenaga-V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Col\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilka","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Correa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"issue":"1","key":"308_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3109\/03630269.2013.832689","volume":"38","author":"MD Bucknor","year":"2014","unstructured":"Bucknor MD, Goo JS, Coppolino ML. The risk of potential thromboembolic, renal and cardiac complications of sickle cell trait. Hemoglobin. 2014;38(1):28\u201332.","journal-title":"Hemoglobin."},{"issue":"1","key":"308_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-199501000-00001","volume":"19","author":"CJ Davis","year":"1995","unstructured":"Davis CJ, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma: the seventh sickle cell nephropathy. Am J Surg Pathol. 1995;19(1):1\u201311.","journal-title":"Am J Surg Pathol."},{"issue":"10","key":"308_CR3","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1002\/pbc.25592","volume":"62","author":"O Alvarez","year":"2015","unstructured":"Alvarez O, Rodriguez MM, Jordan L, Sarnaik S. Renal medullary carcinoma and sickle cell trait: a systematic review. Pediatr Blood Cancer. 2015;62(10):1694\u20139.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"308_CR4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.urology.2007.06.1124","volume":"70","author":"AA Hakimi","year":"2007","unstructured":"Hakimi AA, Koi PT, Milhoua PM, Blitman NM, Li M, Hugec V, et al. Renal medullary carcinoma: the Bronx experience. Urology. 2007;70(5):878\u201382.","journal-title":"Urology"},{"issue":"7","key":"308_CR5","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer Sr","year":"1992","unstructured":"Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10(7):1066.","journal-title":"J Clin Oncol"},{"key":"308_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.urology.2008.05.009","volume":"72","author":"WK Rathmell","year":"2008","unstructured":"Rathmell WK, Monk JP. High-dose-intensity MVAC for advanced renal medullary carcinoma: report of three cases and literature review. Urology. 2008;72:659\u201363.","journal-title":"Urology"},{"key":"308_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pbc.20292","volume":"44","author":"JJ Strouse","year":"2005","unstructured":"Strouse JJ, Spevak M, Mack AK, Arceci RJ, Small D, Loeb DM. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44:407\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"308_CR8","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.purol.2009.11.005","volume":"20","author":"B Diao","year":"2010","unstructured":"Diao B, Paule B, Esquivel S, Abbou CC, Salomon L, De La Taille A. Renal medullary carcinoma: remission with gemcitabine\u2013cisplatin and review of therapeutic perspectives. Prog Urol. 2010;20:538\u201341.","journal-title":"Prog Urol"},{"key":"308_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/pbc.22611","volume":"55","author":"A Walsh","year":"2010","unstructured":"Walsh A, Kelly DR, Vaid YV, Hilliard LM, Friedman GK. Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma. Pediatr Blood Cancer. 2010;55:1217\u201320.","journal-title":"Pediatr Blood Cancer"},{"key":"308_CR10","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/pbc.20292","volume":"44","author":"JJ Strouse","year":"2005","unstructured":"Strouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum-based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005;44:407\u201311.","journal-title":"Pediatr Blood Cancer"},{"key":"308_CR11","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1200\/JCO.2005.05.0344","volume":"24","author":"EA Ronnen","year":"2006","unstructured":"Ronnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 2006;24:e14.","journal-title":"J Clin Oncol"},{"key":"308_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1464-410X.2009.09139.x","volume":"106","author":"EM Schaeffer","year":"2010","unstructured":"Schaeffer EM, Guzzo TJ, Furge KA, et al. Renal medullary carcinoma: molecular, pathological and clinical evidence for treatment with topoisomerase-inhibiting therapy. BJU Int. 2010;106:62\u20135.","journal-title":"BJU Int"},{"issue":"15S","key":"308_CR13","doi-asserted-by":"crossref","first-page":"e16096","DOI":"10.1200\/jco.2009.27.15_suppl.e16096","volume":"27","author":"ED Johnson","year":"2009","unstructured":"Johnson ED, Tannir NN, Olejeme KA, et al. Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol. 2009;27(15S):e16096.","journal-title":"J Clin Oncol"},{"issue":"3","key":"308_CR14","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/PAS.0b013e3182770406","volume":"37","author":"Q Liu","year":"2013","unstructured":"Liu Q, Galli S, Srinivasan R, Linehan WM, Tsokos M, Merino MJ. Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol. 2013;37(3):368\u201374.","journal-title":"Am J Surg Pathol"},{"key":"308_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0090-4295(02)02154-4","volume":"60","author":"MA Swartz","year":"2002","unstructured":"Swartz MA, Karth J, Schneider DT, et al. Renal medullary carcinoma: clinical, pathologic, immunohistochemical, and genetic analysis with pathogenetic implications. Urology. 2002;60:1083\u20139.","journal-title":"Urology"},{"issue":"3","key":"308_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2559.2012.04228.x","volume":"61","author":"J Calderaro","year":"2012","unstructured":"Calderaro J, Moroch J, Pierron G, et al. SMARCB1\/INI1 inactivation in renal medullary carcinoma. Histopathology. 2012;61(3):428\u201335.","journal-title":"Histopathology"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-018-0308-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0308-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-018-0308-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T03:41:36Z","timestamp":1603770096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-018-0308-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["308"],"URL":"https:\/\/doi.org\/10.1007\/s13730-018-0308-3","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"14 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}